Category survey

The Unfolded Protein Response in Neurodegeneration Investments > €500k European Commission Neurodegenerative disease in general 2016    

Structure and Dynamics of Low-Complexity Regions in Proteins: The Huntingtin Case Investments > €500k European Commission Huntington’s disease 2016    

C9orf72-mediated neurodegeneration: mechanisms and therapeutics Investments > €500k European Commission Neurodegenerative disease in general 2016    

Prosaposin and GPR37 in synucleinopathies Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Characterising protein oligomers and their role in neurodegenerative disease in humans Investments > €500k European Commission Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Vascular Engineering on chip using differentiated Stem Cells Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Function and malfunction of the prion protein Investments > €500k European Commission Prion disease 2016    

Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer’s disease Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Hijacking cell signalling pathways with magnetic nanoactuators for remote-controlled stemcell therapies of neurodegenerative disorders Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Molecular mechanism of amyloid beta aggregation Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Biomarker Development for Postoperative Cognitive Impairment in the Elderly Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

The Molecular Anatomy of Neurons Investments > €500k European Commission Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

A systems pharmacology approach to the discovery of novel therapeutics in Alzheimer´s disease Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

From zebrafish to man Modifying amyotrophic lateral sclerosis (ALS): translation of biology into therapy Investments > €500k European Commission Motor neurone diseases 2016    

C9orf72 repeat expansion in FTD/ALS – from mechanisms to therapeutic approaches Investments > €500k European Commission Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Toxic protein aggregation in neurodegeneration Investments > €500k European Commission Neurodegenerative disease in general 2016    

Understanding death-receptor signaling and physiology in the nervous system: A roadmap for the development of new treatments to neurodegenerative diseases and neurotrauma Investments > €500k European Commission Neurodegenerative disease in general 2016    

New experimental therapeutic approaches for Parkinson’s disease by direct DA neuronal reprogramming Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Brain Microcirculation : Numerical simulation for inter-species translation with applications in human health Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Non-Invasive In-Vivo Histology in Health and Disease Using Magnetic Resonance Imaging (MRI) Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

European Prevention of Alzheimer’s Dementia Consortium (EPAD) Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients Investments > €500k European Commission Motor neurone diseases 2016    

The continuum between healthy ageing and idiopathic Parkinson Disease within a propagation perspective of inflammation and damage: the search for new diagnostic, prognostic and therapeutic targets Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Alzheimer’s disease and Zinc: the missing link ? Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Amyotrophic Lateral Sclerosis from a cortical perspective: towards alternative therapeutic strategies Investments > €500k European Commission Motor neurone diseases 2016    

Metabolic and Genetic Regulation of Ageing Investments > €500k European Commission Neurodegenerative disease in general 2016    

Optical imaging of ocular pathology in Alzheimer’s disease Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Study on Environmental and GenomeWide predictors of early structural brain Alterations in Young students Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

The Role of Non-coding RNA in Protein Networks and Neurodegenerative Diseases Investments > €500k European Commission Neurodegenerative disease in general 2016    

The Molecular Communication Mechanism of Motor Neuron Survival and Synapse Maintenance Investments > €500k European Commission Motor neurone diseases 2016    

Protein Misfolding: Prion-like Propagation and Cure. Implications for Neurodegenerative Diseases. Investments > €500k European Commission Neurodegenerative disease in general 2016    

Protection against reactive oxygen species in neurodegeneration Investments > €500k European Commission Motor neurone diseases 2016    

From Patient Data to Clinical Diagnosis in Neurodegenerative Diseases Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

UNDERSTANDING THE CAUSES OF THE RNA GAIN OF FUNCTION DISEASES Investments > €500k European Commission Neurodegenerative disease in general 2016    

Identification and modulation of pathogenic Amyloid beta-peptide species Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Plasticity and formation of lasting memories in health and disease. Genetic modeling of key regulators in adult and aging mammals and in neurodegenerative disease Investments > €500k European Commission Neurodegenerative disease in general 2016    

Cellular determinants of neuronal plasticity on the level of single synapses in vivo Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

What you get is what you see: How Reward Determines Perception Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

A novel two-step model for neurodegeneration in Parkinson’s disease Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

New biomarkers for Alzheimer’s & Parkinson’s diseases – key tools for early diagnosis and drug development Investments > €500k European Commission Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Elucidating early pathogenic mechanisms of neurodegeneration in Parkinson’s disease through a humanized dynamic in vitro model Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

From Cells to Organs on Chips: Development of an Integrative Microfluidic Platform Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Closing the Loop between Understanding and Effective Treatment of the Basal Ganglia and their Disorders Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Aetionomy: Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy Investments > €500k European Commission Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

The analysis of mitochondrial dynamics in ageing and neurodegeneration Investments > €500k European Commission Neurodegenerative disease in general 2016    

METABOLIC BASIS OF NEURODEGENERATIVE DISEASE Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Fast transformation between episodic and semantic memories: Interactions between the hippocampal formation and related regions and their breakdown in Alzheimer’s disease Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Development and application of global lipidomic arrays to inflammatory vascular disease. Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Health and Wellness on the Beat Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016